Vineet Laboratories Limited VINEETLAB NSEINFRA
Company Overview
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2025 Revenue of ₹75.00 Cr (-50.2% YoY); net profit ₹-20.19 Cr.
- Trailing 12 Months Year-on-year growth — revenue -13.4%, earnings -2065.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -26.8%, profit CAGR -134.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -26.80% |
| 1 Year: | -13.40% |
Compounded Profit Growth
| 5 Years: | -134.72% |
| 1 Year: | -2,065.83% |
Stock Price Performance
| 1 Year: | +14.98% |
| 6 Months: | +18.47% |
| 3 Months: | -1.49% |
| 1 Month: | +15.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -26.8% CAGR over 5 years.
- Earnings shrank at -134.7% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VINEETLAB Vineet Laboratories Limited NSEINFRA | 39.00 | -5.20 | ₹74.90 Cr | 0.00% | -84.09% | -137.85% | -26.80% | -134.72% |
| 2 | AMBUJACEM Ambuja Cements Limited NSEINFRA | 436.50 | 24.45 | ₹1.08 L Cr | 0.45% | 4.60% | 7.97% | 8.86% | 34.61% |
| 3 | APLAPOLLO APL Apollo Tubes Limited NIFTY_MIDNSEINFRA | 1,945.00 | 43.97 | ₹54,004.56 Cr | 0.30% | 28.21% | 22.71% | 12.61% | 23.30% |
| 4 | ACUTAAS Acutaas Chemicals Limited NIFTY_SMALLNSEINFRA | 3,260.60 | 91.98 | ₹26,694.90 Cr | 0.05% | 16.51% | 21.52% | 24.34% | 30.18% |
| 5 | AETHER Aether Industries Limited NSEINFRA | 1,584.40 | 89.01 | ₹21,026.98 Cr | 0.00% | 12.15% | 8.94% | 21.23% | 18.94% |
| 6 | AARTIIND Aarti Industries Limited NIFTY_SMALLNSEINFRA | 501.20 | 34.33 | ₹18,179.86 Cr | 0.21% | 8.53% | 7.04% | 8.47% | -8.40% |
| 7 | ANURAS Anupam Rasayan India Ltd NIFTY_SMALLNSEINFRA | 1,213.00 | 78.51 | ₹13,809.80 Cr | 0.12% | 8.66% | 5.76% | 10.10% | -15.03% |
| 8 | ALKYLAMINE Alkyl Amines Chemicals Limited NSEINFRA | 1,921.90 | 54.58 | ₹9,829.78 Cr | 0.76% | 14.54% | 11.74% | -3.01% | -7.67% |
| 9 | ASHAPURMIN Ashapura Minechem Limited NSEINFRA | 729.10 | 17.36 | ₹6,964.81 Cr | 0.14% | 15.10% | 29.05% | 42.85% | 50.82% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.10 Cr | 14.08 Cr | 7.44 Cr | 17.42 Cr | 15.65 Cr |
| Cost of Revenue | 17.27 Cr | 22.25 Cr | 4.61 Cr | 11.82 Cr | 9.78 Cr |
| Gross Profit | 83.02 L | -8.17 Cr | 2.83 Cr | 5.60 Cr | 5.87 Cr |
| Operating Expenses | 5.59 Cr | 3.53 Cr | 3.14 Cr | 3.05 Cr | 4.00 Cr |
| Operating Income | -4.75 Cr | -11.70 Cr | -30.75 L | 2.55 Cr | 1.86 Cr |
| EBITDA | -4.10 Cr | -9.81 Cr | 33.60 L | 3.18 Cr | 2.54 Cr |
| Interest Expense | 95.14 L | 75.30 L | 61.22 L | 2.19 Cr | 1.09 Cr |
| Pretax Income | -5.67 Cr | -11.22 Cr | -90.16 L | 37.16 L | 81.80 L |
| Tax Provision | 3.30 L | -69.63 L | -3.55 L | -2.94 L | -3.27 L |
| Net Income | -5.71 Cr | -10.52 Cr | -86.61 L | 40.10 L | 85.07 L |
| Diluted EPS | -6.19 | - | -0.79 | 0.36 | 0.92 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 191.17 Cr | 212.29 Cr | 150.59 Cr | 75.00 Cr |
| Cost of Revenue | 153.67 Cr | 176.55 Cr | 116.88 Cr | 71.91 Cr |
| Gross Profit | 37.51 Cr | 35.75 Cr | 33.71 Cr | 3.08 Cr |
| Operating Expenses | 26.36 Cr | 30.12 Cr | 29.03 Cr | 21.87 Cr |
| Operating Income | 11.15 Cr | 5.63 Cr | 4.68 Cr | -18.78 Cr |
| EBITDA | 12.85 Cr | 7.06 Cr | 6.73 Cr | -14.44 Cr |
| Interest Expense | 1.49 Cr | 2.66 Cr | 3.85 Cr | 3.83 Cr |
| Pretax Income | 9.35 Cr | 2.03 Cr | 36.34 L | -20.78 Cr |
| Tax Provision | 2.71 Cr | 77.74 L | -66.37 L | -58.45 L |
| Net Income | 6.64 Cr | 1.25 Cr | 1.03 Cr | -20.19 Cr |
| Diluted EPS | 6.02 | 1.14 | 0.93 | -18.40 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 133.32 Cr | 115.85 Cr | 116.87 Cr | 94.54 Cr |
| Current Assets | 102.70 Cr | 87.46 Cr | 88.19 Cr | 67.39 Cr |
| Cash & Equivalents | 16.66 Cr | 63.07 L | 22.78 L | 30.68 L |
| Inventory | 43.54 Cr | 46.17 Cr | 49.39 Cr | 49.97 Cr |
| Receivables | 36.20 Cr | 35.16 Cr | 31.60 Cr | 13.25 Cr |
| Total Liabilities | 100.10 Cr | 82.17 Cr | 82.15 Cr | 79.89 Cr |
| Current Liabilities | 94.77 Cr | 74.51 Cr | 76.00 Cr | 74.39 Cr |
| Long Term Debt | 1.72 Cr | 4.85 Cr | 3.89 Cr | 3.79 Cr |
| Total Debt | 30.70 Cr | 31.09 Cr | 44.30 Cr | 40.05 Cr |
| Total Equity | 33.22 Cr | 33.68 Cr | 34.72 Cr | 14.65 Cr |
| Shares Outstanding | 1.10 Cr | 1.10 Cr | 1.10 Cr | 1.10 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 7.63 Cr | -9.62 Cr | -6.61 Cr | 11.49 Cr |
| Investing Cash Flow | -3.68 Cr | -6.69 Cr | -2.22 Cr | -3.18 Cr |
| Financing Cash Flow | 11.96 Cr | 27.31 L | 8.43 Cr | -8.23 Cr |
| Capital Expenditure | - | -7.63 Cr | -2.79 Cr | -1.05 Cr |
| Free Cash Flow | 7.63 Cr | -17.25 Cr | -9.40 Cr | 10.45 Cr |
| Net Change in Cash | 15.91 Cr | -16.03 Cr | -40.29 L | 7.89 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 19.6% | 16.8% | 22.4% | 4.1% |
| Operating Margin % | 5.8% | 2.7% | 3.1% | -25.0% |
| Net Margin % | 3.5% | 0.6% | 0.7% | -26.9% |
| ROE % | 20.0% | 3.7% | 3.0% | -137.8% |
| ROCE % | 28.9% | 13.6% | 11.5% | -93.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VINEETLAB
Vineet Laboratories Limited Announces Cessation of Gaddam Venkata Ramana to Hold the Office of Managing Director, Effective July 21, 2026 - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOSWQzS1RWMjRyNERIekpKbjdPSk16ZEVzYzFlZVdFank5cGE4MjZEUFd6WXM2ak1weVBYeDNBMGUzVVZ0YTdrdkhIUDNNdWl6QkdGV1lzSUw2N0pMMGNBbHUxSzBiQmpLdml3TmtURjdnMWsxd0hHMVM0Y0pqMTVKLVhCNUhWTzA5aXZUeX…
Vineet Laboratories Completes Rights Issue Allotment of 99,87,258 Equity Shares - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQWld0YmtIVEF4blNQMzloS2xvR2Qtc3BpNFNLaDJneFRtTlN2RWFhWFAydFVhNEVTR29wR0M3U3lUeE1sSk9mdUpHVTlTX0JxakdYajY1ZnVUYkxGT0YwMmhYNnpwN0Z3ZVRiSGNKdE0zcGtGMlRpazdQeEVlenhUM0Judjd5M3RYOXVWV2…
Vineet Laboratories Rights Issue 2025 Date, Price, Allotment, Ratio - IPO Watch
<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE5EOE1qUzNqRjdmRWhnMkh2V0hmdUFMZ1BsNzF5QUJzTnpxM2QyTndMLUp1ZjNQejIycFphY1ZKSzE2WjlBYTlDS2lDTGhsU0tUN3hHbTFOVkxMa2xjUDJvanlocExUdE9rYWc?oc=5" target="_blank">Vineet Laboratories Righ…
Vineet Laboratories Claims SEBI Corporate Governance Exemption for June Quarter - TipRanks
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPWnQwVy1KX2FtUm10NEs5ek5sNDRqc0ZnSFNlQVRwOGhxZ0Y0dWdjcmI2T3FQWUs2VDFtZXBpMl9DSVZwXzAtd2poWnRYck1YZXNid0dJbkJQY2UwMzFreTVoLUlFWmZJcWhVSEg1cmNaRDlnVWJQYzBVbFNYVlFEMklVekFlQ3ppbzlhcl…
VINEETLAB — Frequently Asked Questions
What is the current share price of Vineet Laboratories Limited (VINEETLAB)?
As of 2026-08-07 06:31 IST, Vineet Laboratories Limited (VINEETLAB) trades at ₹39.00 on NSE. Its 52-week range is ₹29.01 to ₹47.87.
What is the market capitalisation of VINEETLAB?
Vineet Laboratories Limited (VINEETLAB) has a market capitalisation of ₹74.90 Cr on NSE.
What is the P/E ratio of VINEETLAB?
VINEETLAB trades at a trailing price-to-earnings (P/E) ratio of -5.20. The industry average P/E is 25.90. Its price-to-book (P/B) ratio is 2.54.
What is the return on equity (ROE) of VINEETLAB?
VINEETLAB has a return on equity (ROE) of -137.85%. Its return on capital employed (ROCE) is -84.09%.
Is VINEETLAB a good stock to buy?
This page provides a data-driven analysis of Vineet Laboratories Limited (VINEETLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.